

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Foundation Health LLC d/b/a Fairbanks Memorial Hospital 2. 1650 Cowles Street Fairbanks, AK 99701		In accordance with letter dated March 14, 2022.	4. Expiration Date: April 30, 2022 under deemed timely renewal
		3. License No.: 50-13648-01 is amended in its entirety to read as follows:	5. Docket No.: 030-03509 Reference No.:
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 3.2 curies total	C. For any use permitted by 10 CFR 35.300.
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed Sources (Bard Brachytherapy, Inc., Model STM 1251)	D. 1.5 curies total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. Palladium-103 permitted by 10 CFR 35.400	E. Sealed Sources (Theragenics Corporation, Model TheraSeed 200)	E. 500 millicuries total	E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 50-13648-01

Docket or Reference No.:
030-03509

Amendment No. 62

6. Byproduct, source,
and/or special nuclear
material

7. Chemical and/or physical form

8. Maximum amount that licensee
may possess at any one time
under this license

9. Authorized use

F. Gadolinium-153

F. Sealed Sources (Eckert &
Ziegler Isotope Products, Model
NES-8412 or A3410; North
American Scientific, Inc., Model
MED 3601)F. 300 millicuries per source
and 1.2 curies totalF. For use in attenuation correction of
gamma camera imaging systems.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 50-13648-01

Docket or Reference No.:
030-03509

Amendment No. 62

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities (Imaging Center and the Heart Center) located at 1650 Cowles Street, Fairbanks, Alaska, 99701

11. The Radiation Safety Officer for this license is David L. Evans, M.D.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users, authorized nuclear pharmacists, and/or authorized medical physicists in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)
Material and Use

Mark Burton, M.D.

35.100; 35.200; 35.300; Gadolinium-153 for attenuation correction in imaging systems

Janice Chen, M.D.

35.100; 35.200; 35.300; Gadolinium-153 for attenuation correction in imaging systems

David L. Evans, M.D.

35.100; 35.200; oral administration of sodium iodide I-131; parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required

Keir Fowler, M.D.

35.100; 35.200; 35.300; Gadolinium-153 for attenuation correction in imaging systems

Richard A. Hattan, M.D.

35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries; Gadolinium-153 for attenuation correction in imaging systems

Douglas Herrin, M.D.

35.100; 35.200; oral administration of sodium iodide I-131

Joel S. Marquess, M.D.

35.100; 35.200; oral administration of sodium iodide I-131

Jessica E. Panko, M.D.

35.100, 35.200; oral administration of sodium iodide I-131

Jordan Ross, M.D.

35.100, 35.200; oral administration of sodium iodide I-131

Timothy Ryan, M.D.

35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 50-13648-01

Docket or Reference No.:
030-03509

Amendment No. 62

Authorized User (M.D., D.O., etc.)

Essam Shihadeh, M.D.

Claire M. Waite, M.D.

Gregory James Wood, D.O.

Romel Wrenn, M.D.

Material and Use

35.400

35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries

35.100; 35.200

35.100; 35.200

13. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 50-13648-01

Amendment No. 62

Docket or Reference No.:
030-03509

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated October 20, 2011 (ML11314A028)
- B. Letter dated April 10, 2012 with attachments (ML121080398)
- C. Letter dated October 26, 2016 (ML16313A129)
- D. Change of control form dated November 22, 2016 (ML16340A720)
- E. Letter dated June 21, 2021 (ML21216A260)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 31, 2022By: _____
Casey Alldredge
Region 4